On August 6, 2025, Nature published a breakthrough study led by Romanian researcher Liviu Aron, working with a distinguished international team. Their research uncovered a clear and compelling connection between lithium deficiency in the brain and the early onset of Alzheimer’s disease.

Alzheimer’s, a progressive neurodegenerative disorder, affects millions worldwide and is a leading cause of cognitive decline and memory loss in aging populations. While there is still no cure, this study sheds new light on a possible therapeutic pathway that could transform how the disease is treated and potentially prevented.

We at Microsin are proud to acknowledge the achievements of Liviu Aron and the entire team of scientists who contributed to this important publication. The dedication, precision, and collaborative effort behind this research exemplify the kind of innovation that drives the pharmaceutical and fine chemicals industries forward. Such studies often take years of foundational work before achieving breakthroughs — and this one is no exception.

Key Findings of the Study

The research team demonstrated that low-dose lithium orotate was capable of reversing Alzheimer’s-like symptoms in mice, with no detectable toxicity. This is a significant finding because many Alzheimer’s treatments under investigation fail due to side effects or poor brain bioavailability.

When compared to lithium carbonate, lithium orotate showed unique and highly relevant advantages:

• No binding to amyloid-β plaques — Amyloid-β plaques are protein accumulations associated with Alzheimer’s pathology. Avoiding binding reduces unwanted interference with existing brain structures.
• Efficient penetration into brain tissue — This allows lithium orotate to reach targeted areas more effectively, potentially improving therapeutic impact.
• Neuroprotective properties — Helps maintain cognitive functions, slows neurodegenerative processes, and may even reverse progression in certain stages.

Microsin SRL — Manufacturing Lithium Orotate Monohydrate Since 2012

Microsin SRL was founded in 1991 as a family-owned company in Romania, specializing in the production of high-purity fine chemicals. Over more than three decades, we have built a reputation for quality, consistency, and compliance with the most rigorous international manufacturing standards.

Since 2012, we have been producing lithium orotate monohydrate in exclusive partnership with Pharmorgana GmbH. This long-standing collaboration ensures our product is available to global research institutions and industrial clients who require dependable quality for their work.

State-of-the-Art Facility in Bucharest

Our production facility, based in Bucharest, Romania’s capital, was designed to meet and exceed international GMP standards. The plant includes:

• Over 50 stainless steel and enamel reactors ranging from 100 to 6000 liters
• Fluid-bed dryers, centrifuges, milling, and distillation systems for precise and controlled production
• Advanced purified water system ensuring product integrity and compliance with pharmacopeia requirements

Quality assurance is central to every stage of our process. We are certified to:

• EU-GMP – Good Manufacturing Practices for pharmaceuticals
• ISO 9001:2015 – Quality Management Systems
• ISO 14001:2015 – Environmental Management Systems
• ISO 45001:2023 – Occupational Health and Safety Management

These certifications guarantee that every batch meets the highest standards of purity, safety, and consistency.

Why This Matters for the Future of Alzheimer’s Research

Lithium orotate has been a subject of interest for decades, but until now, much of the research has been preliminary or inconclusive. This new Nature study changes the conversation by offering concrete evidence in a peer-reviewed, high-impact journal.

For researchers, the next step will be controlled human clinical trials to determine optimal dosage, safety profiles, and efficacy in slowing or reversing Alzheimer’s symptoms in real patients. If successful, lithium orotate could become part of a new class of therapeutic strategies for neurodegenerative diseases.

Our Ongoing Commitment

As the scientific community moves toward these clinical trials, Microsin SRL will continue to supply top-tier lithium orotate monohydrate to research partners worldwide. 

Our mission is to be more than a manufacturer — we aim to be an enabler of progress in neuroscience, pharmaceuticals, and medical research.

Read the full study (Nature, 2025): Lithium deficiency and the onset of Alzheimer’s disease